Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Stocks News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.40 | 15.50 | -0.18% |
| CAC 40 | 7,692.49 | 3.78 | -0.05% |
| DAX 40 | 23,859.89 | 72.44 | 0.30% |
| Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
| FTSE 100 | 8,801.58 | 21.33 | -0.24% |
| HKSE | 23,794.91 | 121.15 | -0.51% |
| NASDAQ | 20,601.10 | 207.97 | 1.02% |
| Nikkei 225 | 39,587.68 | 223.20 | -0.56% |
| NZX 50 Index | 12,764.95 | 1.65 | -0.01% |
| S&P 500 | 6,279.35 | 51.93 | 0.83% |
| S&P/ASX 200 | 8,589.30 | 13.70 | -0.16% |
| SSE Composite Index | 3,473.13 | 0.81 | 0.02% |